Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
The results suggest the potential of semaglutide – the main ingredient in Ozempic and Novo’s higher-dose weight-loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results